StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
BEAMBeam Therapeutics Inc.
stockpulse.co.kr
Nasdaq
$23.84▼ 0.83%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.45BShares out 100M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

9
  • 10.17Closed26.10.17 09:09
    4Ownership#●●●

    Beam Therapeutics Inc.

    John M. Evans, an executive at Beam Therapeutics, filed a Form 4 on October 15, 2026, to report changes in his beneficial ownership of company securities. This filing serves as an official disclosure of insider stock transactions to the SEC.…more

    $23.84-0.83%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.16After-hours26.10.17 05:12
    144Ownership

    Beam Therapeutics Inc.

    Insider John M. Evans of Beam Therapeutics has filed an SEC Form 144 to report a proposed sale of company stock. This is a standard filing disclosing an insider's plan to dispose of shares.…more

    $23.84-0.83%vs prev close
    View filingShare
  • 10.15After-hours26.10.16 05:23
    144Ownership

    Beam Therapeutics Inc.

    John M. Evans, an insider at Beam Therapeutics, has filed SEC Form 144 to report a proposed sale of company shares. This is a standard filing disclosing an insider's plan to dispose of their holdings.…more

    $23.84-0.83%vs prev close
    View filingShare

8 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.13Pre-market26.10.13 20:14
    #●●●#●●●

    Beam Therapeutics to Present Initial Phase 1/2 Data for BEAM-301

    Beam Therapeutics announced initial clinical data for its GSDIa treatment, BEAM-301, demonstrating genetic correction and restored glucose production. The single-dose treatment showed dose-dependent improvements in key clinical endpoints.…more

    $23.84-0.83%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.8Pre-market26.09.08 22:22

    ●●●●●●●● ●●●●● ●●●●●●

    Beam Therapeutics reported positive Phase 1/2 trial data for its AATD treatment, BEAM-302, demonstrating favorable safety and efficacy. The company is now pursuing an accelerated FDA approval pathway and expanding its clinical trials.…more

    $23.84-0.83%vs prev close
    ShareBenzinga
  • 9.8Pre-market26.09.08 19:05

    ●●●●●●●● ●●●●● ●●●●●●

    Beam Therapeutics announced updated phase 1/2 data for its AATD treatment, BEAM-302, demonstrating long-term durability and a consistent safety profile. The company is currently dosing patients in a global pivotal cohort to support potential U.S. accelerated approval.…more

    $23.84-0.83%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →